Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932757 | 1.00 | CHRNA7 (0.39) | CHRNA7ESR1ESR2ACHETDP1 | |
| SCHEMBL1932415 | 1.00 | CHRNA7 (0.39) | CHRNA7ESR1ESR2ACHETDP1 | |
| SCHEMBL14593355 | 0.87 | ESR1 (0.48) | ESR1ESR2NR1I2CES2CES1 | |
| SCHEMBL5755708 | 0.82 | CA2 (0.38) | CHRNA7ESR1ESR2ACHETDP1 | |
| SCHEMBL24408950 | 0.81 | PTPN5 (0.43) | ESR1ESR2NR1I2OGAKDM5B | |
| SCHEMBL24408977 | 0.81 | PTPN5 (0.43) | ESR1ESR2NR1I2OGAKDM5B | |
| SCHEMBL14701578 | 0.81 | PTPN5 (0.43) | ESR1ESR2NR1I2OGAKDM5B | |
| SCHEMBL2175953 | 0.78 | ESR1 (0.65) | ESR1ESR2TDP1CA2CA1 | |
| SCHEMBL1272903 | 0.78 | NR1I2 (0.41) | ESR1ESR2NR1I2CES2CES1 | |
| SCHEMBL1273068 | 0.78 | NR1I2 (0.41) | ESR1ESR2NR1I2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101415643-A | Method for controlling alumina precipitation | ALCOA AUSTRALIA (AU) | 2009-04-22 | — | — | CN | claimed |
| WO-2007112497-A1 | METHOD FOR CONTROLLING THE PRECIPITATION OF ALUMINA | ALCOA OF AUSTRALIA LIMITED (AU) | 2007-10-11 | — | — | WO | claimed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025062119-A2 | NEW COMPOUNDS AND USES THEREOF | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230159762-A1 | NIR TO SWIR FLUORESCENT COMPOUNDS FOR IMAGING AND DETECTION | REVVITY HEALTH SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159762-A1 | NIR TO SWIR FLUORESCENT COMPOUNDS FOR IMAGING AND DETECTION | REVVITY HEALTH SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159762-A1 | NIR TO SWIR FLUORESCENT COMPOUNDS FOR IMAGING AND DETECTION | REVVITY HEALTH SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2007112497-A1 | METHOD FOR CONTROLLING THE PRECIPITATION OF ALUMINA | ALCOA OF AUSTRALIA LIMITED (AU) | 2007-10-11 | — | — | WO | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007089335-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICAL INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-0623103-B1 | PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES | HOECHST SCHERING AGREVO GMBH (DE) | 1997-09-03 | — | — | EP | disclosed |
| US-5608062-A | Process for preparing trifluoromethyl ketones | HOECHST SCHERING AGREVO GMBH (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0623103-A1 | PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES. | HOECHST SCHERING AGREVO GMBH (DE) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014054-A1 | PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES | HOECHST SCHERING AGREVO GMBH (DE) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | CHRNA7 3154/4885ESR1 143/4885ESR2 130/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | CHRNA7 3154/4885ESR1 143/4885ESR2 130/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | CHRNA7 854/4885ESR1 3608/4885ESR2 1477/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | CHRNA7 75/4885ESR1 4505/4885ESR2 2393/4885 |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | CHRNA7 1722/4885ESR1 1603/4885ESR2 465/4885 |
| US-20230159762-A1 | NIR TO SWIR FLUORESCENT COMPOUNDS FOR IMAGING AND DETECTION | SMARCD1, SMARCE1, SMARCB1 | CHRNA7 4185/4885ESR1 3796/4885ESR2 4430/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | CHRNA7 3154/4885ESR1 143/4885ESR2 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.